House Committee Leaders Seek GAO Probe of Drug Prices

November 19, 2009
Allegations that drugmakers are raising prices in anticipation of healthcare legislation that may reduce pharmaceutical costs or curb growth have led several House committee leaders to request a Government Accountability Office (GAO) investigation on recent price trends. Three House Ways and Means Committee members, Chairman Charles Rangel (D-N.Y.), Reps. Pete Stark (D-Calif.) and John Lewis (D-Ga.), and House Energy and Commerce Committee Chairman Henry Waxman (D-Calif.) requested the report in a Nov. 17 letter.
Drug Industry Daily